Windward Bio acquired ex‑China rights to Qyuns Therapeutics’ clinical‑stage bispecific antibody WIN027 (QX027N), targeting TSLP and IL‑13, in a deal valued up to $700 million. Windward said the dual‑target, extended‑half‑life molecule is designed for asthma, COPD and atopic dermatitis and aims to deliver deeper disease control with less frequent dosing. Windward’s purchase complements its earlier immunology deals and follows Novo Holdings’ backing of the biotech. The company highlighted WIN027 as synergistic with its existing anti‑TSLP and other pipeline candidates, targeting a multi‑billion‑dollar respiratory and dermatology market. For antibody developers, the transaction underscores continued demand for bispecific and long‑acting biologics that aim to improve efficacy and dosing convenience in chronic inflammatory diseases.